Low grade inflammation and cardiovascular disease
|
|
- Lesley Clark
- 6 years ago
- Views:
Transcription
1 Low grade inflammation and cardiovascular disease Konstantinos Aznaouridis, MD PhD 1 st Department of Cardiology Hippokration Hospital Athens Medical School
2 Atherosclerosis Start from very young To Old age? 2
3 Inflammation & atherosclerosis Ross R, NEJM 1999
4 RUDOLF VIRCHOW Inflammation-based arterial changes as a mechanism of primary importance in atherogenesis mid 19th century Lamond, B. The American Journal of Pathology
5 INFLAMMATION CHRONIC ACUTE Subclinical, low-grade Inflammatory diseases
6 Inflammation & arterial function Inflammatory substances: mediators or only markers Arterial effects of antiinflammatory treatment Clinical significance of inflammation
7 Inflammation & arterial function
8
9 Chronological or vascular age? Thomas Sydenham A man is as old as his arteries
10 Inflammatory diseases & arterial elastic properties Systemic vasculitis Booth A, Wallace S, McEniery C, et al, Arthr Rheumatism 2004
11 Inflammatory diseases & arterial elastic properties Correlation with disease duration CRP Controls SLE RA Roman M, Devereux R, Schwartz J, et al, Hypertension 2005
12 Inflammatory diseases & arterial elastic properties Adamantiades- Behcet Ikonomidis I, Lekakis J, Stamatelopoulos K, et al, JACC 2004
13 Inflammatory diseases & arterial elastic properties AIx (%) P=0.03 Adamantiades- Behcet ABD controls Ikonomidis I, Aznaouridis K, Protogerou A et al, J Card Fail 2006 Protogerou A, Lekakis J, Stamatelopoulos K et al, Adv Exp Med Biol 2003
14 Inflammatory diseases & arterial elastic properties Kawasaki syndrome Kawasaki AIx 10 P< Kawasaki control control Senzaki H, Chen C-H, Ishido H, et al, Circulation 2005
15 Inflammatory diseases & arterial elastic properties HIV infection Schillaci G, et al, Hypertension 2008 Vlachopoulos C, et al. Artery Research 2009
16 Subclinical inflammation & arterial stiffness General population Higher levels of inflammatory indexes (ie, CRP) correlate with impaired arterial elastic properties Kullo I, et al. Am J Hypertens 2005 Tomiyama et al, Atherosclerosis 2004 Kampus P et al. J Hypertens 2004 Mattace-Raso et al, Atherosclerosis 2004 Yasmin et al, ATVB 2004
17 Subclinical inflammation & arterial stiffness General population % WBC-AIx /μl Vlachopoulos C, Aznaouridis K, et al, Atherosclerosis 2006
18 Subclinical infections & arterial stiffness General population H. Pylori seropositivity PWV m/sec P< sero (+) sero (-) Occult persistent infections have been related to augmented arterial stiffness, indicating an adverse impact on vascular function Saijo Y, Utsugi M, Yoshioka E, et al. Hypertens Res 2005
19 Subclinical inflammation & arterial stiffness Diabetes, Metabolic Syndrome In diabetic pts, the level of CRP and other inflammatory markers correlate with stiffness Wakabayashi I, Masuda H. Clin Chim Acta 2006 In patients with MetS, aortic stiffness correlates with the amount of subcutaneous fat, which composes cytokines and other inflammatory mediators Ferreira I, Henry RMA, Twisk JWR, et al. Arch Intern Med 2005
20 Subclinical inflammation & arterial stiffness Hypercholesterolemia CRP is an independent determinant of c-f PWV in hypercholesterolemic pts Pirro M, Schillaci G, Sayarese G, et al. Eur J Clin Invest 2004
21 Subclinical inflammation & arterial stiffness Hypertension Mahmud A, Feely J. Hypertension 2005 Pietri P, Vyssoulis G, Vlachopoulos C, et al. J Hypertens 2006
22 Acute inflammation and arterial function observational studies Charakida M, Donald A, Terese M et al, Circulation 2005
23 Acute inflammation and arterial function Causal relationship or epiphenomenon? Salmonella Typhi vaccine Vlachopoulos C, Dima I, Aznaouridis K, Stefanadis C. Circulation 2005
24 Acute inflammation and arterial function Acute inflammation impairs elastic properties and increases levels of inflammatory indexes Vlachopoulos C, Dima I, Aznaouridis K, Stefanadis C. Circulation 2005
25 Acute inflammation and arterial function Endothelial function Hingorani AD, Cross J, Kharbanda RΚ et al, Circulation 2000 Kharbanda RK, Walton B, Allen M et al, Circulation 2002 Clapp B, Hierschfield G, Storry C et al, Circulation 2005
26 Inflammatory substances: mediators or only markers
27 Inflammatory mediators / markers Tousoulis D, et al. Eur Heart J 2016
28 Predictive value of CRP General population Predicts CV risk independent of LDL-C and FRS Ridker PM, NEJM 2002
29 Predictive value of inflammatory markers General population The use of contemporary biomarkers (including C-reactive protein) adds only moderately to standard risk factors for risk assessment of individual persons Wang T, et al. NEJM 2006
30 CRP: a protein causing vascular dysfunction and atherosclerosis?
31 CRP: a protein causing vascular dysfunction and atherosclerosis? Αm J Med 2004 Αm J Physiol 2003
32 CRP: a protein causing vascular dysfunction and atherosclerosis? Circulation 2002
33 CRP: a protein causing vascular dysfunction and atherosclerosis? Clapp B, Hierschfield G, Storry C et al, Circulation 2005 Vlachopoulos C, Dima I, Aznaouridis K,et al. Circulation 2005
34 CRP: a protein causing vascular dysfunction and atherosclerosis? ΑΤVB 2005
35 Arterial effects of antiinflammatory treatment
36 Anti-inflammatory drugs and arterial function Maki-Petaja K, Hall F, Booth A et al, Circulation 2006 Chronic inflammatory diseases Rheumatoid arthritis anti-tnf factors
37 Anti-inflammatory drugs and arterial function Chronic inflammatory diseases AIx (%) Corticosteroids in Adamantiades- Behcet disease Controls ABD ABD cort + cort - Protogerou A, Lekakis J,Ikonomidis I et al, Am J Hypertens 2006
38 Anti-inflammatory drugs and arterial function Aspirin in acute inflammation No aspirin pretreatment Aspirin pretreatment Vlachopoulos C, Dima I, Aznaouridis K, Stefanadis C. Circulation 2005
39 Anti-inflammatory drugs and arterial function COX2 inhibitors: celecoxib FMD PWV % P=NS P<0.05 Baseline m/sec P=NS P< Post-smoking Celecoxib Placebo Celecoxib Placebo Vlachopoulos C, Aznaouridis K, Bratsas A et al, Int J Cardiol 2016
40 Anti-inflammatory drugs and arterial function Statins in acute inflammation Vlachopoulos C, Aznaouridis K, et al. Eur Heart J 2007
41 Anti-inflammatory drugs and arterial function ANAKINRA Human recombinant IL-1 receptor antagonist RA patients resistant to dmards Dose: mg/d (24 weeks) s.c Side effects: 1.8% infections, local erythema. Has documented anti- proliferative effects in the coronary artery wall after injury AO DIST Baseline 3h- post placebo 3h- post anakinra post month Ikonomidis I, Lekakis JP, et al. Circulation May 20;117(20):
42 Clinical significance of inflammation
43 Inflammation & coronary syndromes Stefanadis C, Diamantopoulos L, Vlachopoulos C, et al, Circulation 1999
44 Clinical value of inflammation in chronic inflammatory disorders TNF- blockers and CV events in RA patients CV events per 1000 pt-year p= no yes treatment with anti-tnf- Swedish national register of TNF- blockers (n=531), and a control cohort of RA patients (n=452) Jacobsson LT, et al. J Rheumatol 2005;32:
45 Clinical value of acute inflammation 5-fold increase of AMI risk and 3-fold increase of stroke risk following an acute respiratory infection Modest but significant increase of risk following an acute urinary tract infection
46 Clinical value of subclinical inflammation Ridker PM, Lancet 2001
47 Events/100 Person-Yrs Events/100 Person-Yrs Clinical value of subclinical inflammation JUPITER Trial design: Apparently healthy patients with LDL cholesterol <130 mg/dl and hs-crp 2 mg/dl were randomized to rosuvastatin 20 mg daily or placebo. Clinical outcomes were compared at a median of 1.9 years. 2 1 (p < ) (p = 0.02) Results Rosuvastatin associated with a significant in the primary outcome of MI, stroke, unstable angina, revascularization, or cardiovascular death (HR 0.56, 95% CI , p < ) All-cause mortality with rosuvastatin (p = 0.02) 0 Primary outcome 0 All-cause mortality Rosuvastatin was associated with a significant reduction in major cardiovascular events, including death, in patients with LDL <130 mg/dl, but high hs-crp ( 2.0 mg/dl) Rosuvastatin (n = 8,901) Placebo (n = 8,901) Ridker PM, et al. NEJM 2008;359:
48 Clinical value of subclinical inflammation CANTOS Trial design: 10,061 patients with previous MI and hs-crp 2 mg/dl were randomized to canakinumab 50, 150 or 300 mg SC every 3 months or placebo. Clinical outcomes were compared at a median of 48 months.
49 Conclusions - Sufficient data suggest associations between subclinical low grade inflammation (in healthy subjects, general population and subjects with CV risk factors) and clinical inflammation (chronic inflammatory diseases and acute inflammatory disorders) with impaired arterial elastic properties and adverse prognosis. - Evidence suggesting a cause-and-effect relationship is adequate only for acute inflammatory disorders; there are no sufficient data to support a causal association between subclinical low grade inflammation and CV disease in healthy subjects, general population and subjects with CV risk factors but no established CV disease - Data concerning a direct role of CRP in inducing arterial dysfunction are still conflicting - Several anti-inflammatory agents improve arterial performance but further studies are needed to investigate whether this effect is beneficial in terms of prognosis
50 Conclusions
D Terentes-Printzios, C Vlachopoulos, G Vyssoulis, N Ioakeimidis, P Xaplanteris, K Aznaouridis, E Christoforatou, A Samentzas, A Siama, C Stefanadis
Peripheral Vessels Unit, 1st Department of Cardiology Athens Medical School Hippokration Hospital, Athens, Greece D Terentes-Printzios, C Vlachopoulos, G Vyssoulis, N Ioakeimidis, P Xaplanteris, K Aznaouridis,
More informationCanakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) Stable CAD (post MI) On Statin, ACE/ARB, BB, ASA Persistent Elevation of hscrp (> 2 mg/l) N = 10,061 39 Countries April 2011 - June 2017
More informationInflammation and and Heart Heart Disease in Women Inflammation and Heart Disease
Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular
More informationEstrogens vs Testosterone for cardiovascular health and longevity
Estrogens vs Testosterone for cardiovascular health and longevity Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Women vs Men Is there a difference in
More informationTNF-α antagonists improve arterial stiffness in patients with rheumatoid arthritis: a meta-analysis
TNF-α antagonists improve arterial stiffness in patients with rheumatoid arthritis: a meta-analysis G.Georgiopoulos 1, D.Terentes-Printzios 1, C.Vlachopoulos 1, A.Gravos 1, P.Pietri 1, C.Georgakopoulos
More informationINFLAMMATION &THROMBOSIS INSIGHTS FROM CANTOS TRIAL AHMED NADA, FSCAI ALMOSTAKBAL HOSPITAL, JEDDAH SAUDI ARABIA
INFLAMMATION &THROMBOSIS INSIGHTS FROM CANTOS TRIAL AHMED NADA, FSCAI ALMOSTAKBAL HOSPITAL, JEDDAH SAUDI ARABIA Introduction - Two or three decades ago, many experts predicted that the modification of
More informationΛΟΙΜΩΞΗ HIV. Ιγνάτιος Οικονομίδης,MD,FESC Β Πανεπιστημιακή Καρδιολογική
ΛΟΙΜΩΞΗ HIV Ιγνάτιος Οικονομίδης,MD,FESC Β Πανεπιστημιακή Καρδιολογική Κλινική, Νοσοκομείο «Αττικόν» Infection Acute Myocardial Infarction p er 100,000 HIV/AIDS discharg es 800 700 600 500 400 300 200
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationArterial function and longevity Focus on the aorta
Arterial function and longevity Focus on the aorta Panagiota Pietri, MD, PhD, FESC Director of Hypertension Unit Athens Medical Center Athens, Greece Secrets of longevity Secrets of longevity Unveiling
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationCentral pressures and prediction of cardiovascular events in erectile dysfunction patients
Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationLow-density lipoprotein as the key factor in atherogenesis too high, too long, or both
Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili
More informationReducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
New York City Cardiovascular Symposium December 10, 2017 Reducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) Paul M Ridker, MD, MPH
More informationCentral Pressures and Prehypertension
Central Pressures and Prehypertension Charalambos Vlachopoulos Associate Professor of Cardiology 1 st Cardiology Dept Athens Medical School Central Pressures and Prehypertension Charalambos Vlachopoulos
More informationStatin Use and Cardiovascular Disease in HIV
Statin Use and Cardiovascular Disease in HIV Steven K. Grinspoon, MD Professor of Medicine Harvard Medical School Boston, Massachusetts FLOWED: 04/18/16 Los Angeles, California: April 25, 2016 Statin Use
More informationIs it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany
Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany The demographic issue Life expectancy is increasing Patients are getting
More informationsurtout qui n est PAS à risque?
3*25 min et surtout qui n est PAS à risque? 2018 ESC/ESH Hypertension Guidelines 2018 ESC-ESH Guidelines for the Management of Arterial Hypertension 28 th ESH Meeting on Hypertension and Cardiovascular
More informationIs it worth offering cardiovascular disease prevention to the elderly? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany
Is it worth offering cardiovascular disease prevention to the elderly? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany Is it worth offering cardiovascular disease prevention to the elderly?
More informationCRP for the Clinician
CRP for the Clinician J. C. Kaski, D.Sc., M.D., D.M (Hons), F.E.S.C., F.R.C.P., F.A.C.C. F.A.H.A Professor of Cardiovascular Science Head, Cardiovascular Sciences Research Centre St George s, University
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationInflammation as A Target for Therapy. Focus on Residual Inflammatory Risk
ESC Rome Monday August 29, 2016 Inflammation as A Target for Therapy Focus on Residual Inflammatory Risk Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center
More informationHyperlipidemia in an Otherwise Healthy 80 Year-Old Patient. Theodore D Fraker, Jr, MD Professor of Medicine
Hyperlipidemia in an Otherwise Healthy Theodore D Fraker, Jr, MD Professor of Medicine Orlando, Florida October 7-9, 2011 80-Year-Old Patient Primary Prevention Issues in the Elderly: Coronary artery disease
More informationASSOCIATION OF SYSTEMIC INFLAMMATION WITH ARTERIAL STIFFNESS IN HYPERTENSION
ASSOCIATION OF SYSTEMIC INFLAMMATION WITH ARTERIAL STIFFNESS IN HYPERTENSION Jung-Sun Kim a and Sungha Park a,b, a Division of Cardiology, b Cardiovascular Genome Center, Yonsei Cardiovascular Center,
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationDyslipidemia in women: Who should be treated and how?
Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European
More informationSMARTool clinical and biohumoral results. Chiara Caselli IFC-CNR
SMARTool clinical and biohumoral results Chiara Caselli IFC-CNR SMARTool Flow chart EVINCI and ARTreat Populations SMARTool: WP1 and WP2 WP1 Objective: To collect retrospective EVINCI clinical and imaging
More informationTraitements associés chez l hypertendu: Statines, Aspirine
Traitements associés chez l hypertendu: Statines, Aspirine Pr Jean-Jacques Mourad CHU Avicenne, Université Paris 13, Bobigny DU HTA, Mars 2012 jean-jacques.mourad@avc.aphp.fr Global Mortality 2000: Impact
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationPharmacological modulation of vascular structure and function. L. Van Bortel. Heymans Institute of Pharmacology, Ghent University
Pharmacological modulation of vascular structure and function L. Van Bortel Heymans Institute of Pharmacology, Ghent University BHC 2015 Pharmacological modulation of Endothelial function CIMT Pulse wave
More informationSanjay Kaul, MD, FACC, FAHA Division of Cardiology Cedars-Sinai Medical Center Los Angeles, California
Targeting Inflammation in Atherosclerosis: Has CANTOS Nailed It? Controversies and Advances in the Treatment of Cardiovascular Disease The Seventeenth in the Series Beverly Hills, November 16, 2017 Sanjay
More informationInflammation, rheumatoid arthritis and cardiovascular disease
Inflammation, rheumatoid arthritis and cardiovascular disease Yvette Meißner, Pharmacoepidemiology, German Rheumatism Research Centre www. chronische-entzuendung.org Outline I. Cardiovascular disease II.
More informationCentral hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction
Central hemodynamics and prediction of cardiovascular events in patients with erectile dysfunction N.Skliros, N.Ioakeimidis, D.Terentes-Printzios, C.Vlachopoulos Cardiovascular Diseases and Sexual Health
More informationC-Reactive Protein and Your Heart
C-Reactive Protein and Your Heart By: James L. Holly, MD Inflammation is the process by which the body responds to injury. Laboratory evidence and findings at autopsy studies suggest that the inflammatory
More informationAPPLICATION OF PHYSICAL METHODS FOR DETERMINATION OF FUNCTIONAL PARAMETERS OF ARTERIES IN RHEUMATIC PATIENTS
APPLICATION OF PHYSICAL METHODS FOR DETERMINATION OF FUNCTIONAL PARAMETERS OF ARTERIES IN RHEUMATIC PATIENTS Jolanta DADONIENE*, Alma CYPIENE**, Diana KARPEC***, Rita RUGIENE*, Sigita STROPUVIENE*, Aleksandras
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationRheumatoid Arthritis: An update for non rheumatologists
Rheumatoid Arthritis: An update for non rheumatologists Dimitrios Pappas, M.D., M.P.H. Assistant Professor of Medicine Columbia University, College of Physicians & Surgeons Director of Rheumatology Athens
More informationTherapeutic Implications of Vascular Inflammation: The Cardiovascular Inflammation Reduction Trials
Therapeutic Implications of Vascular Inflammation: The Cardiovascular Inflammation Reduction Trials ESC Munich August 25, 2012 Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School
More informationTHE CARDIOVASCULAR INFLAMMATORY CONTINUUM DR AB MAHARAJ
THE CARDIOVASCULAR INFLAMMATORY CONTINUUM DR AB MAHARAJ Disclosures: On National Advisory Boards of: (1) Pfizer Pharmaceuticals (2) MSD (3) Roche Pharmaceuticals (4) Abbott International: AfME Rheumatology
More informationAssociation between arterial stiffness and cardiovascular risk factors in a pediatric population
+ Association between arterial stiffness and cardiovascular risk factors in a pediatric population Maria Perticone Department of Experimental and Clinical Medicine University Magna Graecia of Catanzaro
More informationWeintraub, W et al NEJM March Khot, UN et al, JAMA 2003
Global risk hscrp Should not be included in a Global Cardiovascular Risk Assessment. Jodi Tinkel, MD Assistant Professor Director of Cardiac Rehabilitation Associate Program Director, Cardiovascular Medicine
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationDisclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space?
Disclosures JUPITER: The final frontier in statin utilization or an idea from outer space? Kathy E. Komperda, PharmD, BCPS Midwestern University Chicago College of Pharmacy kkompe@midwestern.edu 4/25/09
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationSubodh Verma, MD PhD FRCSC
CIRT and CANTOS Targeting g Inflammation at in Atherosclerosis e s Subodh Verma, MD PhD FRCSC Cardiac Surgeon, St. Michael s Hospital Associate Professor, Surgery & Pharmacology Canada Research Chair in
More informationVascular disease. Structural evaluation of vascular disease. Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital
Vascular disease. Structural evaluation of vascular disease Goo-Yeong Cho, MD, PhD Seoul National University Bundang Hospital resistance vessels : arteries
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationCorrelation of novel cardiac marker
Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely
More informationWhen Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes
When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes Kim K. Birtcher, MS, PharmD, AACC, FNLA, CLS, BCPS (AQ-Cardiology), CDE Clinical Professor University of Houston College
More informationROLE OF INFLAMMATION IN HYPERTENSION. Dr Barasa FA Physician Cardiologist Eldoret
ROLE OF INFLAMMATION IN HYPERTENSION Dr Barasa FA Physician Cardiologist Eldoret Outline Inflammation in CVDs the evidence Basic Science in Cardiovascular inflammation: The Main players Inflammation as
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationIn-Ho Chae. Seoul National University College of Medicine
The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationSTABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators
STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationDoes High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?
Late Breaking Clinical Trial Session at AHA 2017 Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients With Stable Coronary Artery Disease Takeshi
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationStatins for Cardiovascular Disease Prevention in Women: Review of the Evidence
Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Karen E. Aspry, M.D., M.S., ABCL, FACC Assistant Professor of Medicine (Clinical) Alpert Medical School of Brown University
More informationNew evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy
New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20
More informationPeripheral Vessels Unit, 1st Department of Cardiology Athens Medical School Hippokration Hospital, Athens, Greece
Peripheral Vessels Unit, 1st Department of Cardiology Athens Medical School Hippokration Hospital, Athens, Greece Dimitrios Terentes-Printzios, Charalambos Vlachopoulos, Nikolaos Ioakeimidis, Mahmoud Abdelrasoul,
More informationSanger Heart & Vascular Institute Symposium 2015
Sanger Heart & Vascular Institute Symposium 2015 Cardiovascular Update For Primary Care Physicians William E. Downey, MD FACC FSCAI Medical Director, Interventional Cardiology Sanger Heart & Vascular Institute
More informationFood and plant bioactives for reducing cardiometabolic disease: How does the evidence stack up?
Food and plant bioactives for reducing cardiometabolic disease: How does the evidence stack up? Arrigo F.G. Cicero, MD, PhD Medical and Surgical Sciences Dept., University of Bologna, Italy Italian Nutraceutical
More informationInflammation in Renal Disease
Inflammation in Renal Disease Donald G. Vidt, MD Inflammation is a component of the major modifiable risk factors in renal disease. Elevated high-sensitivity C-reactive protein (hs-crp) levels have been
More informationInflammation, the Inflammasome and CAD Do Cardiologists need to know this? Jacques Genest MD
Inflammation, the Inflammasome and CAD Do Cardiologists need to know this? Jacques Genest MD Cardiovascular Research Laboratories Research Institute of the McGill University Health Center Disclosure J.
More informationThe 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories
The 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories Cardiac biomarkers in atherosclerosis Najma Asadi MD-APCP Ross and Colleagues in 1973: Response to Injury
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationMethods. Background and Objectives STRADIVARIUS
STRADIVARIUS Effect of on Progression of Atherosclerosis in Patients with Abdominal Obesity and Coronary Artery Disease Steven E. Nissen MD Stephen J. Nicholls MBBS PhD, Kathy Wolski MPH, Josep Rodés-Cabau
More informationThe Clinical Debates
The Clinical Debates Speakers: Round 2: Statins for Primary Prevention of Cardiovascular Disease Matthew Cantrell, PharmD, BCPS, is a 2000 graduate of Mt. Mercy College and 2005 graduate from the University
More informationPreventing Early Vascular Ageing (EVA) and its hemodynamic changes
Translational Research 31 st October 2013, Moscow Preventing Early Vascular Ageing (EVA) and its hemodynamic changes Peter M Nilsson, MD, PhD Department of Clinical Sciences Lund University University
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationStatins and endothelium function
Statins and endothelium function Matthias Endres Berlin, Germany Klinik und Poliklinik für Neurologie Conflict of interest: research grant from AstraZeneca from prevention to acute therapy... Pleiotropic
More informationNew Paradigms in Predicting CVD Risk
New Paradigms in Predicting CVD Risk Imaging as an Integrator of Lifetime Risk Exposure Michael J. Blaha MD MPH Presented by: Michael J. Blaha September 24, 2014 1 Talk Outline Risk factors vs. Disease
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 CRESTOR 5 mg, film-coated tablet B/30 (CIP code: 369 853-8) B/90 (CIP code: 391 690-0) CRESTOR 10 mg,
More informationHow to Handle Statin Intolerance in the High Risk Patient
How to Handle Statin Intolerance in the High Risk Patient Thomas D. Conley, MD FACC FSCAI Disclosures: None 1 Definition of High Risk Primary Prevention ASCVD Risk Calculator Adults >21 yrs, LDL 190 mg/dl
More informationCholesteryl ester transfer protein inhibitors - what have we learnt? Philip Barter The Heart Research Institute Sydney, Australia
Cholesteryl ester transfer protein inhibitors - what have we learnt? Philip Barter The Heart Research Institute Sydney, Australia Philip Barter Disclosures Received honorariums for lectures, consultancies
More informationBeyond LDL-Cholesterol
Biomarkers for Risk Stratification Beyond LDL-Cholesterol Athanasios J.Manolis Director Cardioilogy Dep, Asklepeion Hospital, Athens, Greece Adj. Professor of Medicine, Emory University Atlanta, USA Adj.
More informationDyslipidemia 울산의대서울아산병원심장병원심장내과이철환
Dyslipidemia 울산의대서울아산병원심장병원심장내과이철환 Presentation General LDL cholesterol HDL cholesterol Future Summary A top healthcare priority 사망 / 인구 10 만 Causes of Death Worldwide, 2008 140 120 2008 년 한국인 5 대사망원인
More informationSubclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD
Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD Sao Paulo Medical School Sao Paolo, Brazil Subclinical atherosclerosis in CVD risk: Stratification & management Prof.
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationNew Cholesterol Guidelines What the LDL are we supposed to do now?!
New Cholesterol Guidelines What the LDL are we supposed to do now?! Michael D. Shapiro Assistant Professor of Medicine and Radiology Knight Cardiovascular Institute Oregon Health & Science University 2013
More informationCalculating RR, ARR, NNT
Calculating RR, ARR, NNT In a trial RR = Event rate (eg # of people with one stroke/ total people) in treatment group/event rate in the control group. ARR = Event rate in control group minus the event
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationWelcome! Mark May 14, Sat!
Welcome! Mark May 14, Sat! Do We Have All Answers with Statins In Treating Patients with Hyperlipidemia? Kwang Kon Koh, MD, PhD, FACC, FAHA Cardiology, Gil Heart Center, Gachon Medical School, Incheon,
More informationDyslipedemia New Guidelines
Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationEndothelial Function Assessment in Secondary Prevention
Endothelial Function Assessment in Secondary Prevention Amir Lerman, MD Professor of Medicine Chair for Research Cardiovascular Division 2014 MFMER 3319523-1 Multiple Risk Factors 58-y.o. man with CV risk
More informationNon alcoholic fatty liver disease and atherosclerosis Raul Santos, MD
Non alcoholic fatty liver disease and atherosclerosis Raul Santos, MD Sao Paulo Medical School Hospital Sao Paulo, Brazil Disclosure Honoraria received for consult and/or speaker : Astra Zeneca, Amgen,
More informationExpert Meeting on Large Simple Trials (LST s)
Expert Meeting on Large Simple Trials (LST s) Clinical Trials Transformation Initiative Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin JUPITER Johannes
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationHYPERCHOLESTEROLEMIA
UPDATES ON HYPERCHOLESTEROLEMIA WITH EMPHASIS ON PCSK9 INHIBITORS July, 2018 Chicago by Ernesto L. Chua, MD, FACC, FACP, FPCP Board Certified in Internal Medicine Board Certified in Cardiology COL, USAF,
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More information